US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kalaris Therapeutics Inc.

5.39

-0.4300-7.39%

Post-market: 5.520.1300+2.41%19:54 EDT

Volume:173.42K

Turnover:940.30K

Market Cap:123.58M

PE:-1.89

High:5.99

Open:5.86

Low:5.24

Close:5.82

52wk High:11.88

52wk Low:2.14

Shares:22.93M

Float Shares:3.13M

Volume Ratio:2.85

T/O Rate:5.55%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8451

EPS(LYR):-2.8500

ROE:-308.10%

ROA:-45.11%

PB:1.57

PE(LYR):-1.89

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Kalaris Therapeutics Chief Accounting Officer Brett Hagen disposes of USD 12,869 of common shares

Kalaris Therapeutics FY 2025 net loss narrows 37% to USD 43.44 million

Press Release: Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KLRS"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","market":"US","secType":"STK","nameCN":"Kalaris Therapeutics Inc.","latestPrice":5.39,"timestamp":1774641600000,"preClose":5.82,"halted":0,"volume":173422,"hourTrading":{"tag":"盘后","latestPrice":5.52,"preClose":5.39,"latestTime":"19:54 EDT","volume":384,"amount":2120.66,"timestamp":1774655670171,"change":0.13,"changeRate":0.024119,"amplitude":0.024119},"delay":0,"changeRate":-0.07388316151202759,"floatShares":3127100,"shares":22928303,"eps":-2.845069,"marketStatus":"Market Closed","change":-0.43,"latestTime":"03-27 16:00:00 EDT","open":5.86,"high":5.9899,"low":5.24,"amount":940295.471376,"amplitude":0.128849,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.845069,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1596081600000,"exchange":"NASDAQ","adjPreClose":5.82,"postHourTrading":{"tag":"盘后","latestPrice":5.52,"preClose":5.39,"latestTime":"19:54 EDT","volume":384,"amount":2120.66,"timestamp":1774655670171,"change":0.13,"changeRate":0.024119,"amplitude":0.024119},"volumeRatio":2.85013475875116},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","floatShares":3127100,"roa":"-45.11%","roe":"-308.10%","lyrEps":-2.849999,"volumeRatio":2.85013475875116,"shares":22928303,"dividePrice":0,"high":5.9899,"amplitude":0.128849,"preClose":5.82,"low":5.24,"week52Low":2.14,"pbRate":"1.57","week52High":11.88,"institutionHeld":0,"latestPrice":5.39,"eps":-2.845069,"divideRate":0,"volume":173422,"delay":0,"ttmEps":-2.845069,"open":5.86,"prevYearClose":8.44,"prevWeekClose":6.57,"prevMonthClose":10.46,"prevQuarterClose":8.44,"fiveDayClose":6.57,"twentyDayClose":10.46,"sixtyDayClose":8.38},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-17","symbol":"KLRS","fiscalQuarterEnding":"2025/12","expectedEps":-0.56,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1773720000000,"reportTimeType":"pre","actualEps":-0.44},{"market":"US","date":"2025-11-12","symbol":"KLRS","fiscalQuarterEnding":"2025/09","expectedEps":-0.66,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.64},{"market":"US","date":"2025-08-13","symbol":"KLRS","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-0.61},{"market":"US","date":"2025-05-14","symbol":"KLRS","fiscalQuarterEnding":"2025/03","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"pre","actualEps":-2.52},{"market":"US","date":"2025-03-07","symbol":"KLRS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741323600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.3333,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":6,"updateTime":1766548800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRS","date":"2026-03-27","current":-1.894506,"percent":0.177866,"low":-3.702314,"twenty":-2.992198,"median":-1.357057,"eighty":-0.692882,"high":-0.558935,"avg":-1.743367,"sd":1.030415,"marketCap":133442723},"quantilePoints":[{"date":"2025-03-28","current":-2.436259,"twenty":-2.629862,"median":-2.463299,"eighty":-2.415709,"marketCap":168508741},{"date":"2025-04-04","current":-2.000923,"twenty":-2.457891,"median":-2.325397,"eighty":-2.168027,"marketCap":138397856},{"date":"2025-04-11","current":-1.976588,"twenty":-2.405434,"median":-2.167216,"eighty":-1.951712,"marketCap":136714639},{"date":"2025-04-17","current":-1.811647,"twenty":-2.361089,"median":-2.042834,"eighty":-1.880868,"marketCap":125306167},{"date":"2025-04-25","current":-1.762976,"twenty":-2.268073,"median":-1.954956,"eighty":-1.818136,"marketCap":121939732},{"date":"2025-05-02","current":-1.581811,"twenty":-2.177762,"median":-1.903581,"eighty":-1.797045,"marketCap":109409116},{"date":"2025-05-09","current":-1.041021,"twenty":-2.168027,"median":-1.865726,"eighty":-1.715927,"marketCap":72004290},{"date":"2025-05-16","current":-0.871644,"twenty":-2.131794,"median":-1.821111,"eighty":-1.36225,"marketCap":66206559},{"date":"2025-05-23","current":-0.696822,"twenty":-2.051217,"median":-1.811647,"eighty":-0.924751,"marketCap":52927842},{"date":"2025-05-30","current":-0.728832,"twenty":-1.996056,"median":-1.784607,"eighty":-0.873072,"marketCap":55359157},{"date":"2025-06-06","current":-0.765766,"twenty":-1.972262,"median":-1.721064,"eighty":-0.77266,"marketCap":58164519},{"date":"2025-06-13","current":-0.679587,"twenty":-1.946844,"median":-1.576403,"eighty":-0.758379,"marketCap":51618673},{"date":"2025-06-20","current":-0.632803,"twenty":-1.914397,"median":-1.295192,"eighty":-0.733756,"marketCap":48065214},{"date":"2025-06-27","current":-0.630341,"twenty":-1.911693,"median":-0.990998,"eighty":-0.714058,"marketCap":47878190},{"date":"2025-07-03","current":-0.615567,"twenty":-1.898714,"median":-0.913935,"eighty":-0.685496,"marketCap":46756045},{"date":"2025-07-11","current":-0.615567,"twenty":-1.891143,"median":-0.871644,"eighty":-0.649054,"marketCap":46756045},{"date":"2025-07-18","current":-0.595869,"twenty":-1.870593,"median":-0.816242,"eighty":-0.639205,"marketCap":45259851},{"date":"2025-07-25","current":-0.699285,"twenty":-1.8614,"median":-0.765766,"eighty":-0.634773,"marketCap":53114867},{"date":"2025-08-01","current":-0.659888,"twenty":-1.83436,"median":-0.758379,"eighty":-0.635266,"marketCap":50122480},{"date":"2025-08-08","current":-0.667275,"twenty":-1.817055,"median":-0.738681,"eighty":-0.635266,"marketCap":50683552},{"date":"2025-08-15","current":-0.558935,"twenty":-1.812188,"median":-0.724523,"eighty":-0.632803,"marketCap":42454488},{"date":"2025-08-22","current":-0.563436,"twenty":-1.811647,"median":-0.714058,"eighty":-0.627879,"marketCap":46007948},{"date":"2025-08-29","current":-0.815379,"twenty":-1.792178,"median":-0.714058,"eighty":-0.615567,"marketCap":66580608},{"date":"2025-09-05","current":-1.067322,"twenty":-1.785689,"median":-0.715289,"eighty":-0.622954,"marketCap":87153267},{"date":"2025-09-12","current":-0.980287,"twenty":-1.771628,"median":-0.728832,"eighty":-0.627879,"marketCap":80046349},{"date":"2025-09-19","current":-1.005482,"twenty":-1.753242,"median":-0.746068,"eighty":-0.629356,"marketCap":82103615},{"date":"2025-09-26","current":-1.092517,"twenty":-1.715927,"median":-0.758379,"eighty":-0.630341,"marketCap":89210533},{"date":"2025-10-03","current":-1.623887,"twenty":-1.652483,"median":-0.783002,"eighty":-0.631818,"marketCap":132600143},{"date":"2025-10-10","current":-1.059306,"twenty":-1.715927,"median":-0.815379,"eighty":-0.632803,"marketCap":86498683},{"date":"2025-10-17","current":-1.097097,"twenty":-1.652483,"median":-0.853303,"eighty":-0.634281,"marketCap":89584582},{"date":"2025-10-24","current":-1.120001,"twenty":-1.598641,"median":-0.878784,"eighty":-0.635266,"marketCap":91454824},{"date":"2025-10-31","current":-1.085645,"twenty":-1.578566,"median":-0.913935,"eighty":-0.635266,"marketCap":88649461},{"date":"2025-11-07","current":-1.083355,"twenty":-1.543053,"median":-0.93448,"eighty":-0.63822,"marketCap":88462437},{"date":"2025-11-14","current":-1.220778,"twenty":-1.513949,"median":-0.991739,"eighty":-0.641667,"marketCap":99683887},{"date":"2025-11-21","current":-2.326591,"twenty":-1.652483,"median":-1.007772,"eighty":-0.642652,"marketCap":129046684},{"date":"2025-11-28","current":-2.104047,"twenty":-1.7661,"median":-1.019224,"eighty":-0.643637,"marketCap":116703088},{"date":"2025-12-05","current":-1.996147,"twenty":-1.811647,"median":-1.04043,"eighty":-0.647085,"marketCap":110718314},{"date":"2025-12-12","current":-2.808768,"twenty":-1.83375,"median":-1.046709,"eighty":-0.650039,"marketCap":155791141},{"date":"2025-12-19","current":-3.513489,"twenty":-1.853956,"median":-1.059878,"eighty":-0.652009,"marketCap":194879195},{"date":"2025-12-26","current":-3.230252,"twenty":-1.885652,"median":-1.065031,"eighty":-0.655456,"marketCap":179169164},{"date":"2026-01-02","current":-2.845859,"twenty":-1.914397,"median":-1.075338,"eighty":-0.657426,"marketCap":157848407},{"date":"2026-01-09","current":-2.785165,"twenty":-1.996147,"median":-1.083355,"eighty":-0.657426,"marketCap":154481972},{"date":"2026-01-16","current":-2.987477,"twenty":-2.104047,"median":-1.089081,"eighty":-0.657426,"marketCap":165703423},{"date":"2026-01-23","current":-3.29769,"twenty":-2.164782,"median":-1.092517,"eighty":-0.659396,"marketCap":182909648},{"date":"2026-01-30","current":-3.102121,"twenty":-2.196152,"median":-1.097097,"eighty":-0.661858,"marketCap":172062245},{"date":"2026-02-06","current":-2.815512,"twenty":-2.367922,"median":-1.114275,"eighty":-0.662351,"marketCap":156165190},{"date":"2026-02-13","current":-3.02794,"twenty":-2.502772,"median":-1.122292,"eighty":-0.662351,"marketCap":167947713},{"date":"2026-02-20","current":-3.702314,"twenty":-2.785165,"median":-1.136034,"eighty":-0.665305,"marketCap":205352549},{"date":"2026-02-27","current":-3.560695,"twenty":-2.810117,"median":-1.145196,"eighty":-0.674662,"marketCap":197497534},{"date":"2026-03-06","current":-3.262285,"twenty":-2.841832,"median":-1.152067,"eighty":-0.679587,"marketCap":180945894},{"date":"2026-03-13","current":-3.092005,"twenty":-2.933528,"median":-1.165399,"eighty":-0.681064,"marketCap":171501173},{"date":"2026-03-20","current":-2.932075,"twenty":-2.973316,"median":-1.284909,"eighty":-0.685003,"marketCap":127363466},{"date":"2026-03-27","current":-3.072027,"twenty":-2.992198,"median":-1.357057,"eighty":-0.692882,"marketCap":133442723}],"updateTime":1774760783361},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRS\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621081475","title":"Kalaris Therapeutics Chief Accounting Officer Brett Hagen disposes of USD 12,869 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2621081475","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621081475?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:06","pubTimestamp":1774296411,"startTime":"0","endTime":"0","summary":"Brett Hagen, Chief Accounting Officer at Kalaris Therapeutics, reported selling 1,915 shares of common stock at USD 6.72 on March 20, 2026.Following the transaction, Hagen reported directly owning 0 shares of common stock.Hagen reported receiving a stock option for 60,800 shares with an exercise price of USD 6.81 on March 19, 2026.After the grant, Hagen reported directly holding 60,800 stock options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information containe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL7gl18Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kalaris Therapeutics Chief Accounting Officer Brett Hagen disposes of USD 12,869 of common shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"gpt_icon":0},{"id":"2620210104","title":"Kalaris Therapeutics FY 2025 net loss narrows 37% to USD 43.44 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620210104","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620210104?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:04","pubTimestamp":1773749093,"startTime":"0","endTime":"0","summary":"Kalaris published a press release reporting full-year financial results and business updates. For FY 2025, net loss was USD 43.44 million, narrowing 37.2%, while research and development expenses fell 31.7% to USD 30.75 million, mainly due to a USD 32.0 million royalty obligation expense recorded in the prior year. General and administrative expenses rose more than doubled to USD 15.4 million, driven by higher insurance, legal, accounting and other professional fees and personnel costs related to operating as a public company. Cash, cash equivalents and marketable securities totaled USD 117.98 million at year-end, and Kalaris said this is expected to fund operations into the fourth quarter of 2027. On the pipeline, Kalaris reported positive initial Phase 1a single-ascending-dose data for TH103 in treatment-nave nAMD patients, said preliminary Phase 1b/2 data are expected in the first half of 2027, and plans to initiate Phase 3 trials by year-end 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL7SVnXg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4588","IE00BKPKM429.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","NDAQ","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014039.USD","LU2095319765.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","SG9999014005.SGD","BK4112","KLRS","LU2210149790.SGD"],"gpt_icon":0},{"id":"2620212494","title":"Press Release: Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620212494","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620212494?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:00","pubTimestamp":1773748800,"startTime":"0","endTime":"0","summary":"Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027. Intend to initiate Phase 3 clinical trials by year-end 2027. Completed oversubscribed $50.0 million private placement in December 2025. $118.0 million in cash, cash equivalents and marketable securities as of December 31, 2025 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones. \"This past year was truly transformational for Kalaris,\" said Andrew Oxtoby, Chief Executive Officer of Kalaris Therapeutics. \"Following our initial listing as a public company in March 2025, we continued to advance our clinical program for TH103 throughout the year, culminating with the disclosure of positive initial Phase 1a single ascending dose data and concurrent oversubscribed private placement. In Q3 2025, we began to enroll patients in our Phase 1b/2 multiple ascending dose trial which is desi","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CST","BK4139","KLRS"],"gpt_icon":0},{"id":"2616323222","title":"Kalaris Therapeutics Inc  expected to post a loss of 53 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2616323222","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616323222?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:45","pubTimestamp":1772545505,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics Inc  expected to post a loss of53cents a share - Earnings Preview Kalaris Therapeutics Inc KLRS.OQ KLRS.O is expected to  report resultson March 5 (estimated) for the period endin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL8N3ZR1PZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/KLRS\",params:#limit:6,delay:false,,,undefined,":[]}}